$Regencell Bioscience(RGC.US) fell -12%, behind which is an ongoing securities class action lawsuit—the deadline for lead plaintiff claims from investors just passed, and the market is starting to take seriously the company's foundation of zero revenue and continuous net losses. The previous wave of impulsive gains lacked earnings support from the start, relying on narrative and liquidity; once the lawsuit enters the process, the valuation pressure on small caps is persistent, not a negative that can be digested in a single day.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
